• Alvotech recently reported first-quarter 2026 results showing net income of US$1.03 million compared with US$109.68 million a year earlier, alongside a prior revenue decline tied to production slowdowns and facility improvements.
• Days later, the FDA completed a routine cGMP surveillance inspection of Alvotech’s Reykjavik site and issued a Form 483, which the company says involves remediable observations and supports its plan to resubmit key Biologics License Applications in 2026.
• We’ll now examine how the FDA Form 483 and related BLA resubmissions may affect Alvotech’s biosimilar growth narrative and risk profile.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Alvotech Investment Narrative Recap

To own Alvotech, you need to believe its expanding biosimilar portfolio can convert regulatory clearances into durable, partner-led revenues despite lumpier milestone timing. The recent FDA Form 483 looks manageable based on the company’s comments and appears unlikely, on its own, to derail the key near term catalyst of US BLA resubmissions, though it does underline that regulatory timing remains the main operational risk right now.

In that context, the Q1 2026 update matters: net income fell sharply year on year and revenue was hit by production slowdowns linked to facility upgrades, yet Alvotech still reaffirmed its 2026 revenue guidance of US$650 million to US$700 million. That reaffirmation now sits against an FDA inspection outcome that will be closely watched as investors weigh how fast those planned approvals and launches can translate into the guided milestones.

Yet while the FDA’s observations may look manageable at first glance, investors should still recognise the risk that regulatory timing and milestone driven revenues could...

Alvotech's narrative projects $980.5 million revenue and $189.6 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $14.00 fair value, a 329% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this inspection, assuming revenue could reach about US$1.1 billion and earnings US$326 million by 2029, which contrasts sharply with concerns about pipeline concentration and inspection related approval timing, and shows how widely your view on Alvotech’s risk and reward can differ once you factor in this new regulatory wrinkle.

Explore 5 other fair value estimates on Alvotech - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.